Table 2:

Methodologic quality assessment of included cohorts

StudyDefined sample*Representative sampleFollow-up rate > 80%Follow-up time§Prognosis
Bakker et al.10YesNoYesYesYes
Bousema et al.11YesNoYesYesYes
Breen et al.12YesNoNoNoNo
Carey et al.13
Sundararajan et al.14
Carey et al.15YesYesNoYesYes
Costa et al.16YesYesYesYesYes
Coste et al.17YesYesYesYesYes
Coste et al.18YesYesYesYesYes
Epping-Jordan et al.19
Shaw et al.20
Wahlgren et al.21
Williams et al.22
Faber et al.23YesYesYesYesYes
Ferguson et al.24,25YesNoYesYesYes
Gatchel et al.26,27YesNoNoYesNo
Grotle et al.2,28YesNoYesYesYes
Gurcay et al.29YesYesYesYesYes
Hasenbring et al.30YesYesYesYesYes
Hazard et al.31
Reid et al.32
Heneweer et al.33YesYesYesYesYes
Henschke et al.3YesYesYesYesYes
Klenerman et al.34YesNoNoYesYes
Koleck et al.35YesYesYesYesYes
Kovacs et al.36YesNoYesNoYes
Lehmann et al.37YesNoYesYesYes
Melloh et al.38YesYesYesYesYes
Poiraudeau et al.39YesYesYesYesYes
Reeser et al.40YesYesNoYesYes
Schiottz-Christensen et al.41YesNoYesYesYes
Shaw et al.42-44YesNoYesYesYes
Sieben et al.45YesNoNoYesYes
Sieben et al.46YesNoNoYesYes
Suri et al.47YesYesNoNoYes
Swinkels-Meewisse et al.48YesNoNoYesYes
Thomas et al.49YesNoYesYesNo
Valat et al.50YesNoYesNoYes
  • * Description of source of patients and inclusion and exclusion criteria.

  • Participants were selected as consecutive cases.

  • Outcome data were available for at least 80% of participants at one follow-up point.

  • § At least one prognostic outcome was followed up at three months or later.

  • Raw data, percentages, survival rates or continuous outcome reported.